Thank you for subscribing!
Next Investors Jul 31, 2024
Our Biotech Investments have been the shining lights in our Portfolio over the last 12 months. Given this form, in June we took a pretty big swing at the INOVIQ (ASX:IIQ) placement and added IIQ to our biotech Portfolio.
Next Investors Jul 11, 2024
There are currently no approved treatments available to help children with Autism Spectrum Disorder (ASD). Our biotech Investment Neurotech International (ASX: NTI) is looking to change this.
Next Investors Jun 12, 2024
Our new Investment Inoviq (ASX: IIQ) is at the forefront of a new frontier in biotechnology.
Next Investors Jun 08, 2024
Biotechs have been a good sector for us over the last 18 months, while the rest of the market was terrible.
Get expert stock analysis direct in your inbox
Next Investors Jun 07, 2024
Our biotech Investment, Arovella Therapeutics (ASX: ALA) is developing an iNKT cell therapy platform to fight cancer, and is setting the stage for a Phase 1 clinical trial. Basically ALA’s treatment can find, identify and kill specific cancer cells, leaving other healthy cells unharmed,
Next Investors Apr 17, 2024
Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.
Next Investors Mar 26, 2024
Our Investment ALA is trialling a technology to find, target and attack ONLY cancer cells, leaving the rest of the body healthy and unimpacted.
Next Investors Mar 20, 2024
We are Invested in Neurotech International (ASX: NTI) - a clinical stage biotech company.
Next Investors Mar 12, 2024
Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB), just announced success on its interim Phase III clinical trial for FSGS - a rare kidney disease.
Next Investors Mar 08, 2024
Yesterday, our biotech investment Emyria (ASX:EMD) was up 37% on no news.
Next Investors Feb 24, 2024
In this week's trading sessions, we noticed many long ignored stocks in our portfolio and on our watchlist were seeing little nibbles of buying.
Next Investors Feb 19, 2024
Neurotech International (ASX: NTI) is currently running a Phase I/II clinical trial for Rett Syndrome.
Next Investors Jan 30, 2024
Arovella Therapeutics (ASX:ALA) licensed a new technology today that promises to significantly boost the effectiveness of the company’s solid tumour therapy.
Wise-Owl Jan 24, 2024
Neurotech International (ASX: NTI) is developing an oral drug treatment that is being clinically trialled with children suffering from some of the negative effects of autism.
Next Investors Sep 09, 2023
In this Weekender, we look at the high-risk, high-reward landscape of biotech investing, early-stage companies offer outsized returns on successful clinical trials, aligning perfectly with our investment strategy and providing a unique opportunity to contribute to groundbreaking advancements in medical science.
Next Investors Jan 28, 2023
In this weekly wrap, we look at the various outlooks presented by the media toward our key investment themes such as; biotechs, resources and technology companies.
Finfeed Sep 02, 2022
Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment in DXB is currently sitting below that price at 14.5 cents.
Finfeed Feb 18, 2022
Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.
Join Our Mailing List
